# Phase II Study of Range and Schedule of rPA Doses

> **NCT00170456** · PHASE2 · COMPLETED · sponsor: **PharmAthene UK Limited** · enrollment: 415 (actual)

## Conditions studied

- Prevention of Bacillus Anthracis (Anthrax) Infection

## Interventions

- **BIOLOGICAL:** rPA vaccine containing alhydrogel

## Key facts

- **NCT ID:** NCT00170456
- **Lead sponsor:** PharmAthene UK Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-01
- **Final completion:** 2007-02
- **Target enrollment:** 415 (ACTUAL)
- **Last updated:** 2008-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00170456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00170456, "Phase II Study of Range and Schedule of rPA Doses". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00170456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*